New drug shows promise for Tough-to-Treat throat cancer

NCT ID NCT03848286

Completed Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a drug called KL-A167 in 153 adults with recurrent or metastatic nasopharyngeal carcinoma (a type of throat cancer). Participants received the drug by IV every two weeks. The main goal was to see how many patients' tumors shrank or disappeared. The study is complete, and results will help determine if this drug is safe and effective enough for further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KL-A167 (a drug given by IV every 2 weeks)
What this could lead to: If it works, this could offer a new treatment option for people with advanced nasopharyngeal cancer that has come back or spread.
What could go wrong: This is a mid-stage trial with no control group, so results are preliminary. The drug may not work for everyone and could cause side effects like immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma Neoplasm Metastasis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA RECURRENT OR METASTATIC

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.